SCHEMBL1481728

SCHEMBL1481728

O=C(O)c1ccc(-c2ccc(/C=C/c3nc(-c4ccc(Cl)cc4Cl)c[nH]3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
SRD5A2 P31213 2/20 0.49
ALPL P05186 1/20 0.42
MARS1 P56192 1/20 0.41
EIF4E P06730 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ATM Q13315 1/20 0.38
CTRC Q99895 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
MAPT P10636 2/20 0.38
MAP2K4 P45985 1/20 0.38
HPGD P15428 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481731 1.00 SMN1; SMN2 (0.52) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL6532951 0.90 KDM4E (0.43) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481017 0.89 ITGB2 (0.46) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481016 0.89 ITGB2 (0.46) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481013 0.89 ITGB2 (0.46) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481422 0.89 KDM4E (0.45) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481419 0.89 KDM4E (0.45) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1480766 0.88 PTGES (0.44) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1480764 0.88 PTGES (0.44) SMN1; SMN2KDM4ENPC1RAB9ACRHBP
SCHEMBL1481885 0.86 SMN1; SMN2 (0.49) SMN1; SMN2KDM4ENPC1RAB9ACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885KDM4E 672/4885NPC1 3792/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885KDM4E 672/4885NPC1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.